ID   PEO4
AC   CVCL_2690
SY   PE04; PEO-4
DR   BTO; BTO:0005797
DR   EFO; EFO_0005448
DR   ArrayExpress; E-MTAB-691
DR   BioGRID_ORCS_Cell_line; 993
DR   cancercelllines; CVCL_2690
DR   CancerTools; 151673
DR   Cell_Model_Passport; SIDM00471
DR   Cosmic; 1709261
DR   DepMap; ACH-001632
DR   ECACC; 10032309
DR   GEO; GSM185147
DR   GEO; GSM185148
DR   GEO; GSM459657
DR   GEO; GSM459854
DR   GEO; GSM743510
DR   GEO; GSM851939
DR   GEO; GSM1340590
DR   GEO; GSM2475002
DR   GEO; GSM4973222
DR   GEO; GSM4973228
DR   GEO; GSM4973234
DR   GEO; GSM4973240
DR   GEO; GSM4973252
DR   GEO; GSM4973264
DR   GEO; GSM4973246
DR   GEO; GSM4973258
DR   GEO; GSM4973270
DR   PRIDE; PXD003668
DR   PRIDE; PXD020764
DR   Progenetix; CVCL_2690
DR   Wikidata; Q54947168
DR   Ximbio; 151673
RX   CelloPub=CLPUB00667;
RX   PubMed=1348364;
RX   PubMed=3167863;
RX   PubMed=3583449;
RX   PubMed=8824553;
RX   PubMed=9041185;
RX   PubMed=19654294;
RX   PubMed=20581869;
RX   PubMed=22183581;
RX   PubMed=22328975;
RX   PubMed=22710073;
RX   PubMed=23415752;
RX   PubMed=25230021;
RX   PubMed=25960936;
RX   PubMed=27235858;
RX   PubMed=27561551;
RX   PubMed=28273451;
RX   PubMed=30971826;
RX   PubMed=35028612;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 59 hours (PubMed=3583449); 36 hours (PubMed=3167863); 75.67 hours (CelloPub=CLPUB00667).
CC   HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02; DRB1*11:01,04:05 (PubMed=25960936).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr1655Tyr (c.4965C>T) (5193C>T); ClinVar=VCV001657967; Zygosity=Hemizygous; Note=De novo mutation that cancels the c.4965C>G (5193C>G) mutation in the patient (PubMed=19654294).
CC   Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg160Trp (c.478A>T); ClinVar=VCV000412204; Zygosity=Homozygous (CelloPub=CLPUB00667; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Asp (c.731G>A); ClinVar=VCV000372785; Zygosity=Homozygous (CelloPub=CLPUB00667; PubMed=25230021; PubMed=28273451; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Genome sequenced.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): DepMap; ECACC; PubMed=22183581; PubMed=22710073; PubMed=25230021
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 10
ST   D16S539: 9
ST   D18S51: 16,17
ST   D19S433: 13,15
ST   D21S11: 30,32.2
ST   D2S1338: 20,21
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 13,14
ST   FGA: 20
ST   Penta D: 9,14
ST   Penta E: 11,12
ST   TH01: 9.3
ST   TPOX: 9,11
ST   vWA: 15,16
DI   NCIt; C36101; BRCA2-associated hereditary breast and ovarian cancer syndrome
DI   NCIt; C5228; Ovarian cystadenocarcinoma
DI   ORDO; Orphanet_145; Hereditary breast and ovarian cancer syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2686 ! PEO1
OI   CVCL_2691 ! PEO6
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 36
//
RX   CelloPub=CLPUB00667;
RA   Lisio M.-A.;
RT   "Evaluation of platinum-sensitivity in a cell line model of high grade
RT   serous ovarian cancer and the induction of resistance from a chemo-
RT   sensitive cell line through the repopulation of cells following
RT   short-term cisplatin treatment.";
RL   Thesis PhD (2019), McGill University Montreal, Canada.
//
RX   PubMed=1348364; DOI=10.1073/pnas.89.7.3070;
RA   Godwin A.K., Meister A., O'Dwyer P.J., Huang C.-S., Hamilton T.C.,
RA   Anderson M.E.;
RT   "High resistance to cisplatin in human ovarian cancer cell lines is
RT   associated with marked increase of glutathione synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992).
//
RX   PubMed=3167863;
RA   Langdon S.P., Lawrie S.S., Hay F.G., Hawkes M.M., McDonald A.,
RA   Hayward I.P., Schol D.J., Hilgers J., Leonard R.C.F., Smyth J.F.;
RT   "Characterization and properties of nine human ovarian adenocarcinoma
RT   cell lines.";
RL   Cancer Res. 48:6166-6172(1988).
//
RX   PubMed=3583449; DOI=10.1002/ijc.2910390607;
RA   Wolf C.R., Hayward I.P., Lawrie S.S., Buckton K., McIntyre M.A.,
RA   Adams D.J., Lewis A.D., Scott A.R.R., Smyth J.F.;
RT   "Cellular heterogeneity and drug resistance in two ovarian
RT   adenocarcinoma cell lines derived from a single patient.";
RL   Int. J. Cancer 39:695-702(1987).
//
RX   PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#;
RA   Mullen P., Ritchie A., Langdon S.P., Miller W.R.;
RT   "Effect of Matrigel on the tumorigenicity of human breast and ovarian
RT   carcinoma cell lines.";
RL   Int. J. Cancer 67:816-820(1996).
//
RX   PubMed=9041185;
RA   Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.;
RT   "Increased platinum-DNA damage tolerance is associated with cisplatin
RT   resistance and cross-resistance to various chemotherapeutic agents in
RT   unrelated human ovarian cancer cell lines.";
RL   Cancer Res. 57:850-856(1997).
//
RX   PubMed=19654294; DOI=10.1158/0008-5472.CAN-09-1178;
RA   Sakai W., Swisher E.M., Jacquemont C., Chandramohan K.V., Couch F.J.,
RA   Langdon S.P., Wurz K., Higgins J., Villegas E., Taniguchi T.;
RT   "Functional restoration of BRCA2 protein by secondary BRCA2 mutations
RT   in BRCA2-mutated ovarian carcinoma.";
RL   Cancer Res. 69:6381-6386(2009).
//
RX   PubMed=20581869; DOI=10.1038/onc.2010.245;
RA   Cooke S.L., Ng C.K.Y., Melnyk N., Garcia M.J., Hardcastle T., Temple J.,
RA   Langdon S.P., Huntsman D.G., Brenton J.D.;
RT   "Genomic analysis of genetic heterogeneity and evolution in high-grade
RT   serous ovarian carcinoma.";
RL   Oncogene 29:4905-4913(2010).
//
RX   PubMed=22183581; DOI=10.1002/path.3980;
RA   Ng C.K.Y., Cooke S.L., Howe K.L., Newman S., Xian J., Temple J.,
RA   Batty E.M., Pole J.C.M., Langdon S.P., Edwards P.A.W., Brenton J.D.;
RT   "The role of tandem duplicator phenotype in tumour evolution in
RT   high-grade serous ovarian cancer.";
RL   J. Pathol. 226:703-712(2012).
//
RX   PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170;
RA   Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D.,
RA   Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B.,
RA   Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A.,
RA   Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.;
RT   "Genomic complexity and AKT dependence in serous ovarian cancer.";
RL   Cancer Discov. 2:56-67(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028;
RA   Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F.,
RA   Noonan A.M., Annunziata C.M.;
RT   "Characterization of ovarian cancer cell lines as in vivo models for
RT   preclinical studies.";
RL   Gynecol. Oncol. 142:332-340(2016).
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645;
RA   Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y.,
RA   Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.;
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645.1-12645.14(2016).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35028612; DOI=10.1016/j.xcrm.2021.100471;
RA   Huang D.-Q., Chowdhury S., Wang H., Savage S.R., Ivey R.G., Kennedy J.J.,
RA   Whiteaker J.R., Lin C.-W., Hou X.-N., Oberg A.L., Larson M.C., Eskandari N.,
RA   Delisi D.A., Gentile S., Huntoon C.J., Voytovich U.J., Shire Z.J.,
RA   Yu Q., Gygi S.P., Hoofnagle A.N., Herbert Z.T., Lorentzen T.D.,
RA   Calinawan A., Karnitz L.M., Weroha S.J., Kaufmann S.H., Zhang B.,
RA   Wang P., Birrer M.J., Paulovich A.G.;
RT   "Multiomic analysis identifies CPT1A as a potential therapeutic target
RT   in platinum-refractory, high-grade serous ovarian cancer.";
RL   Cell Rep. Med. 2:100471.1-100471.32(2021).
//